Advertisements

Rexahn Pharmaceuticals Inc. (RNN) Stock Quote

Detailed Quote for Rexahn Pharmaceuticals Inc. (RNN)
$ 2.11   0.05 (+2.43%) Volume: 207.89k 8:00 PM EST Jan 18, 2018
After Hours:  $ 2.07   -0.04 (-1.90%) Volume: 420 5:07 PM EST Jan 18, 2018
Today 5d 1m 3m 1y more
Last Price
2.11
Change $
0.05
Change %
2.43%
Tick
  
Bid
N/A
Bid Size
0
Ask
3.00
Ask Size
100
Open
2.08
High
2.14
Low
2.03
Prev Close
2.06
Last Trade
01/18/18
Volume
207.89k
52 Wk Hi
7.0999999
52 Wk Low
1.671
Market Cap
66.94m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
31,725,114
EPS (TTM)
-0.889999985
PE Ratio
N/A
Exchange
NYSE American
News and Media for Rexahn Pharmaceuticals Inc. (RNN)
Sector News | Topic News
News for Rexahn Pharmaceuticals Inc. (RNN)
Thu, Jan 18, 2018
9:00 AM Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting - GlobeNewswire
Mon, Jan 08, 2018
9:00 AM Rexahn Pharmaceuticals to Present at Biotech Showcase(TM) 2018 - GlobeNewswire
Thu, Jan 04, 2018
9:00 AM Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer - GlobeNewswire
Mon, Dec 11, 2017
9:00 AM Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin(TM) at the 2017 San Antonio Breast Cancer Symposium - GlobeNewswire
Thu, Nov 16, 2017
1:49 PM Rexahn Pharmaceuticals (RNN) Presents At Stifel 2017 Healthcare Conference - Slideshow - SeekingAlpha
Thu, Nov 09, 2017
9:00 AM Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference - GlobeNewswire
Wed, Nov 08, 2017
10:37 AM Mid-stage study underway assessing Rexahn's RX-3117 in pancreatic cancer - SeekingAlpha
9:00 AM Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane\u00AE in Patients Newly Diagnosed with Metastatic Pancreatic Cancer - GlobeNewswire
Tue, Nov 07, 2017
8:00 AM Today's Research Reports on Trending Tickers: Rexahn Pharmaceuticals and Idera Pharmaceuticals - ACCESSWIRE IA
Mon, Nov 06, 2017
9:26 AM Rexahn Pharmaceuticals reports Q3 results - SeekingAlpha
9:00 AM Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire
Fri, Oct 13, 2017
12:45 PM Midday Gainers / Losers - SeekingAlpha
9:43 AM Rexahn Pharma secures $8M private capital raise; shares down 24% - SeekingAlpha
9:23 AM Premarket Losers as of 9:05 am - SeekingAlpha
8:59 AM Rexahn Announces $8 Million Registered Direct Offering - GlobeNewswire
Thu, Oct 12, 2017
8:14 PM 3 Potential Long Ideas From Today's Relative Volume Scan - SeekingAlpha
Tue, Oct 10, 2017
9:02 AM Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117 - GlobeNewswire
Fri, Oct 06, 2017
7:16 AM Premarket analyst action - healthcare - SeekingAlpha
Thu, Sep 21, 2017
9:00 AM Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC - GlobeNewswire
Mon, Sep 11, 2017
9:43 AM Rexahn Pharma updates on pipeline candidates Supinoxin and RX-3117; shares ahead 6% - SeekingAlpha
More News for RNN >>

Tags for Rexahn Pharmaceuticals Inc.

Research stocks or mutual funds related to Rexahn Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to RNN. The keywords below have been associated to RNN by either user submission or electronic means.

Drugs Healthcare Common Stock Pharmaceutical Preparation Manufacturing (325412) Pharmaceutical Preparations (2834)